Vivani Medical, Inc. 8-K

What Happened
Vivani Medical, Inc. (VANI) filed a Form 8-K reporting two material developments. On March 25, 2026 the board adopted — and the company’s stockholders approved at its 2026 Annual Meeting — an amendment and restatement of the Vivani Medical, Inc. 2022 Omnibus Incentive Plan that increases the pool of common stock available for awards. Separately, on June 25, 2026 Vivani announced that Bellberry (an Australian human research ethics committee) approved initiation of SLIM-1™, a Phase 1 clinical trial of NPM-139, Vivani’s semaglutide implant.

Key Details

• The 2022 Omnibus Incentive Plan reserve was increased by 11,000,000 shares, from 10,033,333 to 21,033,333 shares.
• The board adopted the amended and restated plan on March 25, 2026; the amendment was described in Vivani’s proxy statement filed April 29, 2026 and approved by stockholders at the Annual Meeting.
• Bellberry granted ethics approval on June 25, 2026 to start SLIM-1™, a Phase 1 study of NPM-139 (a semaglutide implant).
• The company filed the 8-K on June 30, 2026 to report these events.

Why It Matters
Increasing the equity award pool gives Vivani flexibility to grant stock-based compensation and incentives to employees, directors or consultants, but it also increases the potential for share dilution if and when awards are issued. The Bellberry approval to start a Phase 1 clinical trial is an early but important operational milestone for Vivani’s lead product candidate, NPM-139; it enables the company to begin human testing, which will produce data investors can use to assess clinical progress. Investors should watch for announcements about trial enrollment, timing of initial data, and any future equity awards or filings that could affect share count.